Evogene Ltd. (EVGN)
Company Overview
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $312,000 | $4M | $0.44 |
| Q2 2025 | $884,000 | -$4M | $-0.62 |
| Q1 2025 | $2M | -$3M | $-0.38 |
| Q4 2024 | $2M | $427,000 | $0.06 |
Source: Company filings
Chart & Info
Price Chart
Evogene Ltd. (EVGN) stock price: $1.05 (+0.02, +1.94%)
Why Bull
- •Recent insider buying suggests those in the know see value, signaling potential upside. It's like Musk loading up on Tesla before a big announcement.
- •Community sentiment is leaning bullish, with many seeing long-term potential in their technology. Think of the early days of CRISPR stocks.
- •Market perception is shifting positively, with increasing mentions in innovation-focused discussions. Similar to how AI stocks caught fire.
- •Positive developments in their partnerships are fueling optimism about future revenue streams. Reminds me of Gilead's early HIV drug deals.
Why Bear
- •Some insiders selling shares raises concerns about their confidence in the company's near-term prospects. Like executives cashing out before a downturn.
- •Bearish community members are questioning the scalability of their technology. Echoes the doubts surrounding early solar energy companies.
- •Market perception includes skepticism about their ability to compete with larger players. Similar to concerns about smaller biotechs facing pharma giants.
- •Delays in key product launches are creating uncertainty about their growth trajectory. Recalls the challenges faced by some electric vehicle startups.
Latest News
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Feb 4, 2026
Technical Analysis
Rationale
AI-generated technical analysis for EVGN including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Evogene Ltd. (EVGN) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for EVGN.
Make a Prediction
Set your price target for Evogene Ltd. (EVGN), choose a timeframe, and track your prediction accuracy.
Current price: $1.05 · Analyst target: $3.50
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVGN.
Price Targets
Consensus target: $3.50
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 8/100
Revenue grew 50.9% YoY, showing strong top-line momentum well above industry average.
-
Gross Margin 8/100
Gross margin at 44.0% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Limited cash of $15M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 10/100
Investing 167.5% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 3/100
Extreme turnover at 14.30% signals potential mania; rapid price swings and volatility are likely.
-
Price Momentum 2/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates EVGN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Frequently Asked Questions
Is EVGN a good stock to buy?
Whether EVGN is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the EVGN MoonshotScore?
The MoonshotScore for EVGN is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is EVGN data updated?
EVGN stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to EVGN is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for EVGN?
Growth catalysts for Evogene Ltd. (EVGN) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Evogene Ltd.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are EVGN's main competitors?
Evogene Ltd. (EVGN) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether EVGN has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about EVGN?
Wall Street analyst coverage for EVGN includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is EVGN's market cap?
Market capitalization (market cap) for EVGN is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows EVGN's current market cap alongside enterprise value and other valuation metrics.
How has EVGN stock performed recently?
EVGN's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing EVGN's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in EVGN?
Key risk categories for EVGN include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures EVGN's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling EVGN?
Insider trading activity for EVGN tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is EVGN a good stock for beginners?
Evogene Ltd. (EVGN) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is EVGN for first-time investors?
Every stock carries risk, including Evogene Ltd. (EVGN). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like EVGN.
EVGN vs S&P 500: which is better for new investors?
The S&P 500 (SPY) offers broad diversification across 500 large U.S. companies, making it a lower-risk starting point for new investors. Evogene Ltd. (EVGN) is a single stock with higher potential upside but also more concentrated risk. Most financial advisors suggest new investors start with index funds like the S&P 500 and gradually add individual stocks like EVGN as they gain experience. Compare EVGN's MoonshotScore and volatility to the broad market before deciding.
What should beginners know before buying EVGN?
Before buying Evogene Ltd. (EVGN), beginners should understand: (1) the company's business model and how it makes money (see the Company Overview on this page), (2) its financial health through revenue growth and gross margins (see MoonshotScore Breakdown), (3) what analysts are saying (check the Analyst Consensus tab), and (4) the key risks (see Risk Factors). Start with a small position you are comfortable losing entirely, and consider dollar-cost averaging instead of investing a lump sum.
How much money do I need to start investing in EVGN?
You can start investing in Evogene Ltd. (EVGN) with as little as $1 through fractional shares, which most modern brokers offer. There is no minimum investment required. However, financial experts typically recommend only investing money you will not need for at least 3-5 years. Before buying EVGN, make sure you have an emergency fund covering 3-6 months of expenses and no high-interest debt. Check the current EVGN share price at the top of this page.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.